Novartis' chronic heart failure treatment Entresto, Janssen's anti-inflammatory medicine Stelara, and Bayer and Janssen's blood clotting drug Xarelto will no longer be part of CMS' Medicare Drug Price Negotiation Program, starting Jan. 1, 2027.
They are exiting the program because regulators determined they now face generic or biosimilar competition (drugs can only be selected for negotiations if there is a lack of bona fide competition from generic or biosimilar competitors). Please note these three drugs will continue to be a part of the Medicare negotiation program for 2026 and their maximum fair prices (MFP's) will apply. Be prepared for the Medicare Drug Price Negotiation Program, which kicks off in one short month for the first 10 drugs. Enroll in the Medicare Transaction Facilitator today if you haven't already! For more information on how to enroll and other helpful details, click here.
